Treatment of neurodegenerative disease with sodium chlorite
AssigneesNeuvivo, Inc., The Regents of the University of California
InventorsVernon A. NORVIEL, Michael S. McGrath
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Claims22
A method comprising:
- a) administering to a subject who has dementia a regimen of an amount of a compound that is therapeutically-effective for the dementia;
- and
- b) monitoring a plasma level of C-reactive protein in the subject during the regimen and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
- wherein in the subject, the compound is converted to hypochlorite and the hypochlorite is converted to a chloramine after interaction with taurine.
A method of treating a dementia in a subject in need thereof, the method comprising:
- a) administering to a subject who has dementia a regimen of an amount of a compound that is therapeutically-effective for the dementia;
- and
- b) monitoring a plasma level of C-reactive protein in the subject during the regimen and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
- wherein in the subject, the compound is converted to hypochlorite and the hypochlorite is converted to a chloramine after interaction with taurine;
- wherein the amount of the compound that is therapeutically-effective for the dementia is about 1.5 mg/kg/day to about 3.5 mg/kg/day and the administering occurs on each of about five days over one week;
- wherein the administering is intravenous infusion;
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
- wherein the administering is by administration of a formulation, wherein the formulation comprises:
- a) the compound;
- and b) phosphate buffer, wherein the formulation has a pH of about 7 to about 9.5;
- wherein the dementia is Amyotrophic Lateral Sclerosis (ALS);
- wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises quantifying the C-reactive protein in a biological sample of the subject;
- and
- wherein the subject is human.
Dependencies are inferred from the claim text.